Evidence map›Paper›PMID 33150361›Full record

ArticleBrain : a journal of neurology2020

Protein contributions to brain atrophy acceleration in Alzheimer's disease and primary age-related tauopathy.

Keith A Josephs, Peter R Martin, Stephen D Weigand, Nirubol Tosakulwong, Marina Buciuc, Melissa E Murray, Leonard Petrucelli, Matthew L Senjem, Anthony J Spychalla, David S Knopman and 6 more

Open access · bronzeAbstract read
In one paragraph

Article in Brain : a journal of neurology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed
6.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 86 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Primary age-related tauopathy.Acta neuropathologica · 2025
    Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Polypathologic Associations with Gray Matter Atrophy in Neurodegenerative Disease.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2024
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 1 country.

Keith A JosephsDepartment of Neurology (Behavioral Neurology), Mayo Clinic, Rochester, MN, USA.
Peter R MartinDepartment of Health Science Research (Biostatistics), Mayo Clinic, Rochester, MN, USA.
Stephen D WeigandDepartment of Health Science Research (Biostatistics), Mayo Clinic, Rochester, MN, USA.
Nirubol TosakulwongDepartment of Health Science Research (Biostatistics), Mayo Clinic, Rochester, MN, USA.
Marina BuciucDepartment of Neurology (Behavioral Neurology), Mayo Clinic, Rochester, MN, USA.
Melissa E MurrayDepartment of Neuroscience (Neuropathology), Mayo Clinic, Jacksonville, FL, USA.
Leonard PetrucelliDepartment of Neuroscience (Molecular Neuroscience), Mayo Clinic, Jacksonville, FL, USA.
Matthew L SenjemDepartment of Radiology (Radiology Research) Mayo Clinic, Rochester, MN, USA.
Anthony J SpychallaDepartment of Radiology (Radiology Research) Mayo Clinic, Rochester, MN, USA.
David S KnopmanDepartment of Neurology (Behavioral Neurology), Mayo Clinic, Rochester, MN, USA.
Bradley F BoeveDepartment of Neurology (Behavioral Neurology), Mayo Clinic, Rochester, MN, USA.
Ronald C PetersenDepartment of Neurology (Behavioral Neurology), Mayo Clinic, Rochester, MN, USA.
Joseph E ParisiDepartment of Laboratory Medicine and Pathology (Neuropathology), Mayo Clinic, Rochester, MN, USA.
Dennis W DicksonDepartment of Neuroscience (Neuropathology), Mayo Clinic, Jacksonville, FL, USA.
Clifford R JackDepartment of Radiology (Radiology Research) Mayo Clinic, Rochester, MN, USA.
Jennifer L WhitwellDepartment of Radiology (Radiology Research) Mayo Clinic, Rochester, MN, USA.
Mayo Clinic in Florida · USMayo Clinic in Arizona · USMayo Clinic · US

Funding

SUPPLEMENT TO ALZHEIMERS DISEASE PATIENT REGISTRYU01AG006786 · NIA · MAYO CLINIC ROCHESTER · PI GRAFF-RADFORD, JONATHAN, JACK, CLIFFORD R. · 1986 to 2023
$49.6M
Research Education ComponentP30AG062677 · NIA · MAYO CLINIC ROCHESTER · PI Walter K. Kremers · 2019 to 2026
$33.5M
PREDICTING ALZHEIMERS DISEASE WITH MAGNETIC RESONANCER01AG011378 · NIA · MAYO CLINIC ROCHESTER · PI JACK, CLIFFORD R. · 1993 to 2017
$12.1M
Disease pathways in the population determined by amyloid, tau, and neurodegeneration imaging biomarkersR37AG011378 · NIA · MAYO CLINIC ROCHESTER · PI CLIFFORD R. JACK · 2018 to 2026
$6.8M
Understanding the role of TDP-43 in Alzheimers disease and FTLDR01AG037491 · NIA · MAYO CLINIC ROCHESTER · PI JOSEPHS, KEITH A · 2010 to 2024
$6.5M
Validating the New Criteria for Preclinical Alzheimer's diseaseR01AG041851 · NIA · MAYO CLINIC ROCHESTER · PI JACK, CLIFFORD R., KNOPMAN, DAVID S · 2012 to 2021
$6.3M
NIA NIH HHS P30 AG062677NIA NIH HHS R01 AG011378NIA NIH HHS R01 AG037491NIA NIH HHS R01 AG041851NIA NIH HHS R37 AG011378NIA NIH HHS U01 AG006786
6 · The paper itself

Abstract

Alzheimer's disease is characterized by the presence of amyloid-β and tau deposition in the brain, hippocampal atrophy and increased rates of hippocampal atrophy over time. Another protein, TAR DNA binding protein 43 (TDP-43) has been identified in up to 75% of cases of Alzheimer's disease. TDP-43, tau and amyloid-β have all been linked to hippocampal atrophy. TDP-43 and tau have also been linked to hippocampal atrophy in cases of primary age-related tauopathy, a pathological entity with features that strongly overlap with those of Alzheimer's disease. At present, it is unclear whether and how TDP-43 and tau are associated with early or late hippocampal atrophy in Alzheimer's disease and primary age-related tauopathy, whether either protein is also associated with faster rates of atrophy of other brain regions and whether there is evidence for protein-associated acceleration/deceleration of atrophy rates. We therefore aimed to model how these proteins, particularly TDP-43, influence non-linear trajectories of hippocampal and neocortical atrophy in Alzheimer's disease and primary age-related tauopathy. In this longitudinal retrospective study, 557 autopsied cases with Alzheimer's disease neuropathological changes with 1638 ante-mortem volumetric head MRI scans spanning 1.0-16.8 years of disease duration prior to death were analysed. TDP-43 and Braak neurofibrillary tangle pathological staging schemes were constructed, and hippocampal and neocortical (inferior temporal and middle frontal) brain volumes determined using longitudinal FreeSurfer. Bayesian bivariate-outcome hierarchical models were utilized to estimate associations between proteins and volume, early rate of atrophy and acceleration in atrophy rates across brain regions. High TDP-43 stage was associated with smaller cross-sectional brain volumes, faster rates of brain atrophy and acceleration of atrophy rates, more than a decade prior to death, with deceleration occurring closer to death. Stronger associations were observed with hippocampus compared to temporal and frontal neocortex. Conversely, low TDP-43 stage was associated with slower early rates but later acceleration. This later acceleration was associated with high Braak neurofibrillary tangle stage. Somewhat similar, but less striking, findings were observed between TDP-43 and neocortical rates. Braak stage appeared to have stronger associations with neocortex compared to TDP-43. The association between TDP-43 and brain atrophy occurred slightly later in time (∼3 years) in cases of primary age-related tauopathy compared to Alzheimer's disease. The results suggest that TDP-43 and tau have different contributions to acceleration and deceleration of brain atrophy rates over time in both Alzheimer's disease and primary age-related tauopathy.

Indexed as

AgedAged, 80 and overAlzheimer DiseaseAtrophyAutopsyBrainDNA-Binding ProteinsFemaleHippocampusHumansLongitudinal StudiesMagnetic Resonance ImagingMaleNeocortexNeurofibrillary TanglesRetrospective StudiesDNA-Binding ProteinsTARDBP protein, humanBraak stagelongitudinalPARTrate of atrophyTDP-43

Identifiers

PMID33150361
PMCPMC7719030
OpenAlexW3096471621

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.